0000899243-19-000988.txt : 20190110 0000899243-19-000988.hdr.sgml : 20190110 20190110172539 ACCESSION NUMBER: 0000899243-19-000988 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190110 FILED AS OF DATE: 20190110 DATE AS OF CHANGE: 20190110 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Caracciolo Anthony CENTRAL INDEX KEY: 0001258929 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-49908 FILM NUMBER: 19520967 MAIL ADDRESS: STREET 1: 1111 MAIN STREET, SUITE 660 CITY: VANCOUVER STATE: WA ZIP: 98660 FORMER NAME: FORMER CONFORMED NAME: CARACCIOLO ANTHONY DATE OF NAME CHANGE: 20030807 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CytoDyn Inc. CENTRAL INDEX KEY: 0001175680 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 753056237 STATE OF INCORPORATION: DE FISCAL YEAR END: 0531 BUSINESS ADDRESS: STREET 1: 1111 MAIN STREET, SUITE 660 CITY: VANCOUVER STATE: WA ZIP: 98660 BUSINESS PHONE: 360-980-8524 MAIL ADDRESS: STREET 1: 1111 MAIN STREET, SUITE 660 CITY: VANCOUVER STATE: WA ZIP: 98660 FORMER COMPANY: FORMER CONFORMED NAME: CYTODYN INC DATE OF NAME CHANGE: 20031114 FORMER COMPANY: FORMER CONFORMED NAME: REXRAY CORP DATE OF NAME CHANGE: 20020617 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-01-10 1 0001175680 CytoDyn Inc. CYDY 0001258929 Caracciolo Anthony 1111 MAIN STREET, SUITE 660 VANCOUVER WA 98660 1 0 0 0 Stock Options (right to buy) 0.64 2019-01-10 4 D 0 100000 D 2019-05-29 Common Stock 100000 0 D Stock Options (right to buy) 0.64 2019-01-10 4 A 0 100000 A 2024-05-29 Common Stock 100000 100000 D Stock Options (right to buy) 0.66 2019-01-10 4 D 0 50000 D 2019-06-01 Common Stock 50000 0 D Stock Options (right to buy) 0.66 2019-01-10 4 A 0 50000 A 2024-06-01 Common Stock 50000 50000 D The reported transactions involve the amendment of certain outstanding options to extend the expiration date of each by a period of five years, resulting in (for purposes of Section 16 of the Exchange Act of 1934, as amended) the deemed cancellation of the "old" option and the grant of a replacement option. There have been no changes in the exercise prices of such options, which were all at or above the closing sale price of the issuer's common stock as of the date of the reported transactions. Such options were fully vested and exercisable as of the date of the reported transactions. /s/ Michael D. Mulholland, as attorney-in-fact 2019-01-10